Local Adjuvant Treatment with Low-Dose CpG-B Offers Durable Protection against Disease Recurrence in Clinical Stage I-II Melanoma: Data from Two Randomized Phase II Trials

Bas D. Koster, Mari F. C. M. van den Hout, Berbel J. R. Sluijter, Barbara G. Molenkamp, Ronald J. C. L. M. Vuylsteke, Arnold Baars, Paul A. M. van Leeuwen, Rik J. Scheper, M. Petrousjka van den Tol, Alfons J. M. van den Eertwegh, Tanja D. de Gruijl*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)5679-5686
Number of pages8
JournalClinical Cancer Research
Volume23
Issue number19
DOIs
Publication statusPublished - 1 Oct 2017

Keywords

  • SENTINEL LYMPH-NODE
  • T-CELL REACTIVITY
  • DENDRITIC CELLS
  • CD8(+) T
  • SURVIVAL
  • ACTIVATION
  • VACCINATION
  • ANTIGEN

Cite this

Koster, B. D., van den Hout, M. F. C. M., Sluijter, B. J. R., Molenkamp, B. G., Vuylsteke, R. J. C. L. M., Baars, A., van Leeuwen, P. A. M., Scheper, R. J., van den Tol, M. P., van den Eertwegh, A. J. M., & de Gruijl, T. D. (2017). Local Adjuvant Treatment with Low-Dose CpG-B Offers Durable Protection against Disease Recurrence in Clinical Stage I-II Melanoma: Data from Two Randomized Phase II Trials. Clinical Cancer Research, 23(19), 5679-5686. https://doi.org/10.1158/1078-0432.CCR-17-0944